Take off with Precigen Inc. (PGEN): Get ready for trading

Precigen Inc. (NASDAQ: PGEN) stock jumped 0.92% on Tuesday to $2.19 against a previous-day closing price of $2.17. With 1.58 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.81 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.2300 whereas the lowest price it dropped to was $2.0500. The 52-week range on PGEN shows that it touched its highest point at $3.00 and its lowest point at $1.12 during that stretch. It currently has a 1-year price target of $7.80. Beta for the stock currently stands at 1.90.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PGEN was up-trending over the past week, with a rise of 4.78%, but this was up by 48.98% over a month. Three-month performance surged to 27.33% while six-month performance rose 20.33%. The stock lost -22.06% in the past year, while it has gained 44.08% so far this year. A look at the trailing 12-month EPS for PGEN yields -0.41 with Next year EPS estimates of -0.44. For the next quarter, that number is -0.10. This implies an EPS growth rate of 21.20% for this year and -414.30% for next year. EPS is expected to grow by 2.40% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 20.90%.

Float and Shares Shorts:

At present, 200.67 million PGEN shares are outstanding with a float of 183.37 million shares on hand for trading. On Dec 29, 2022, short shares totaled 6.79 million, which was 3.26% higher than short shares on Nov 29, 2022. In addition to Mr. Randal J. Kirk J.D. as the firm’s Exec. Chairman, Dr. Helen Sabzevari MPH, Ph.D. serves as its Pres, CEO & Director.

Institutional Ownership:

Through their ownership of 61.07% of PGEN’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 9.35% of PGEN, in contrast to 52.59% held by mutual funds. Shares owned by individuals account for 10.66%. As the largest shareholder in PGEN with 3.23% of the stake, BlackRock Fund Advisors holds 6,717,246 shares worth 6,717,246. A second-largest stockholder of PGEN, The Vanguard Group, Inc., holds 4,872,924 shares, controlling over 2.34% of the firm’s shares. Iridian Asset Management LLC is the third largest shareholder in PGEN, holding 3,209,904 shares or 1.54% stake. With a 1.39% stake in PGEN, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 2,901,233 shares are owned by the mutual fund manager. The iShares Russell 2000 ETF, which owns about 1.10% of PGEN stock, is the second-largest Mutual Fund holder. It holds 2,295,089 shares valued at 3.49 million. JPMorgan Funds – Thematics – Gene holds 0.79% of the stake in PGEN, owning 1,653,431 shares worth 2.51 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Sep 29, 2022, PGEN reported revenue of $2.91M and operating income of -$23.52M. The EBITDA in the recently reported quarter was -$20.22M and diluted EPS was -$0.09.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PGEN since 4 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With PGEN analysts setting a high price target of $14.00 and a low target of $6.00, the average target price over the next 12 months is $8.28. Based on these targets, PGEN could surge 539.27% to reach the target high and rise by 173.97% to reach the target low. Reaching the average price target will result in a growth of 278.08% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. PGEN will report FY 2022 earnings on 02/27/2024. Analysts have provided yearly estimates in a range of -$0.41 being high and -$0.41 being low. For PGEN, this leads to a yearly average estimate of -$0.41. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Precigen Inc. surprised analysts by $0.10 when it reported -$0.04 EPS against a consensus estimate of -$0.14. The surprise factor in the prior quarter was $0.01. Based on analyst estimates, the high estimate for the next quarter is -$0.05 and the low estimate is -$0.12. The average estimate for the next quarter is thus -$0.10.

Summary of Insider Activity:

Insiders traded PGEN stock several times over the past three months with 4 Buys and 0 Sells. In these transactions, 58,986 shares were bought while 0 shares were sold. The number of buy transactions has increased to 34 while that of sell transactions has risen to 5 over the past year. The total number of shares bought during that period was 1,549,580 while 263,661 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *